Potential gene therapy for patients with rare disease

Potential gene therapy for patients with rare disease
Dr Umaimainthan Palendira and Associate Professor Stuart Tangye

Australian scientists have discovered that a biological phenomenon known as ‘somatic reversion’, when an abnormal gene spontaneously becomes normal again, explains why some patients with a rare genetic disorder live much longer than they should.

The finding provides hope for future gene therapy treatments.

Dr Umaimainthan Palendira and Associate Professor Stuart Tangye, from Sydney’s Garvan Institute of Medical Research, realised that a substantial percentage of patients with the rare immunodeficiency known as X-linked lymphoproliferative disease (XLP) were living much longer than expected, and were even approaching the age of 50. Many XLP patients die before they reach 10 years of age, and the majority have a life expectancy of less than 40 years.

The anomaly was explained when Palendira and Tangye found that in longer-living patients – and within a small population of their immune (a subset of ‘killer T cells’ known as ‘effector T cells’) – their abnormal gene had reverted to being normal again. This was enough to confer some protection against infection with the Epstein Barr Virus (EBV), which is often deadly for people with XLP. These findings are published in the Journal of Experimental Medicine, now online.

“Somatic reversion is a fascinating clinical phenomenon, which has been characterised in a handful of other rare diseases, but never before seen in XLP,” said Associate Professor Stuart Tangye.

“Our finding highlights the importance of effector T cells in the case of XLP. This is clinically relevant because it tells us that you only need a small population of cells that are functionally capable of responding to EBV to give you good immune protection.”

“If XLP were to receive gene therapy in future, it should be possible to confer some protection by getting the gene into a only a small number of effector T cells - a very targeted therapy.”

normally works by modifying bone marrow stem cells – the precursor cells which give rise to all of your blood cells, including T cells, B cells, platelets and macrophages.”

“In this case, you would insert the normal gene only into naïve T cells, those T cells which have never seen infection before. When these precursor cells then encounter EBV infection, they would divide and multiply, giving rise to effector T cells, which actually work against EBV.”

“While we don’t yet know exactly how somatic reversion works in XLP, we can see that it does, and that fact has clinical implications for the future.”

add to favorites email to friend print save as pdf

Related Stories

Gene clue to how virus causes cancer

Mar 19, 2012

Virologists and immunologists at Imperial College London and University of Zurich have identified mutations in Epstein-Barr virus (EBV) that increase the capacity of the virus to cause cancer, in a study published ...

New glandular fever, genes and MS link

Jul 22, 2011

(Medical Xpress) -- Scientists working on the Australian-based Ausimmune Study have discovered that a past infection with glandular fever, also known as the Epstein-Barr virus (EBV), combined with genetic ...

Correcting sickle cell disease with stem cells

Sep 28, 2011

(Medical Xpress) -- Using a patient’s own stem cells, researchers at Johns Hopkins have corrected the genetic alteration that causes sickle cell disease (SCD), a painful, disabling inherited blood disorder that affects ...

DNA 'off switch' may reverse premature aging

Jun 15, 2011

The secret to preventing or reversing premature aging may be found in a DNA “off switch” that humans share with common yeast, according to new research from the University of Toronto.

Recommended for you

Neutralising antibodies for safer organ transplants

12 hours ago

Serious complications can arise following kidney transplants. If dialysis is required within the first seven days, then the transplanted organ is said to have a Delayed Graft Function (DGF), and essentially ...

User comments